It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Longitudinal bone growth, achieved through endochondral ossification, is accomplished by a cartilaginous structure, the physis or growth plate, comprised of morphologically distinct zones related to chondrocyte function: resting, proliferating and hypertrophic zones. The resting zone is a stem cell-rich region that gives rise to the growth plate, and exhibits regenerative capabilities in response to injury. We discovered a FoxA2+group of long-term skeletal stem cells, situated at the top of resting zone, adjacent the secondary ossification center, distinct from the previously characterized PTHrP+ stem cells. Compared to PTHrP+ cells, FoxA2+ cells exhibit higher clonogenicity and longevity. FoxA2+ cells exhibit dual osteo-chondro-progenitor activity during early postnatal development (P0-P28) and chondrogenic potential beyond P28. When the growth plate is injured, FoxA2+ cells expand in response to trauma, and produce physeal cartilage for growth plate tissue regeneration.
The growth plate cartilage supports long bone growth. Here the authors identify FoxA2+ long term stem cells in the growth plate that are stratified with short term PTHrP+ cells, participate in production of hyaline cartilage, expand in response to trauma, and whose ablation impairs cartilage regeneration.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details








1 134 Mugar Life Sciences Building, Northeastern University, Department of Biology, Boston, USA (GRID:grid.261112.7) (ISNI:0000 0001 2173 3359)
2 Beth Israel Deaconess Medical Center, Centre for Advanced Orthopedic Studies, Boston, USA (GRID:grid.239395.7) (ISNI:0000 0000 9011 8547)
3 University of Oviedo, Division of Pediatrics, Oviedo, Spain (GRID:grid.10863.3c) (ISNI:0000 0001 2164 6351)
4 New York University College of Dentistry, New York, USA (GRID:grid.137628.9) (ISNI:0000 0004 1936 8753)
5 Moderna Therapeutics, Ohio, USA (GRID:grid.479574.c) (ISNI:0000 0004 1791 3172)
6 Beth Israel Deaconess Medical Center, Centre for Advanced Orthopedic Studies, Boston, USA (GRID:grid.239395.7) (ISNI:0000 0000 9011 8547); Chemistry, and Medicine, Boston University, Departments of Biomedical Engineering, Boston, USA (GRID:grid.189504.1) (ISNI:0000 0004 1936 7558)
7 Boston Children’s Hospital, Department of Orthopedic Surgery, Boston, USA (GRID:grid.2515.3) (ISNI:0000 0004 0378 8438)
8 Chemistry, and Medicine, Boston University, Departments of Biomedical Engineering, Boston, USA (GRID:grid.189504.1) (ISNI:0000 0004 1936 7558)
9 Infection, and Immunity, Harvard School of Dental Medicine, Department of Oral Medicine, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X)
10 Ultragenyx Pharmaceutical, Cambridge, USA (GRID:grid.430528.8) (ISNI:0000 0004 6010 2551)
11 Harvard School of Dental Medicine, Department of Developmental Biology, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X)